Lifecore Biomedical Inc

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q3 2025

Lifecore Biomedical explores strategic alternatives and strengthens supply agreements

Lifecore Biomedical's Q3 2023 performance was steady, with strategic strengths in supply agreements and expertise in pharmaceutical injectable-grade HA. However, challenges from timing shifts and inflationary pressures were evident. The company anticipates increased revenue-generating capacity and sees opportunities in expanded supply agreements.

Lifecore Biomedical explores strategic alternatives amidst revenue decline and debt challenges

Lifecore Biomedical's Q2 2023 performance reflects revenue decline, lower gross profit, and challenges from heavy debt burden. The company's strategic review process, led by Morgan Stanley, aims to maximize shareholder value through potential sales or financing transactions. Despite uncertainties leading to the withdrawal of fiscal outlook, Lifecore maintains a proactive stance in addressing operational and financial challenges.

Lifecore Biomedical strengthens partnerships and capacity for future growth

Lifecore Biomedical navigated challenges in Q3 2023 with a focus on strategic partnerships, capacity investments, and a vision for significant revenue growth in the future.
Despite a decrease in financial metrics for the quarter, Lifecore's strengths in CDMO services, development portfolio, and agreements with Alcon position it for long-term success.
Opportunities for growth lie in expanding HA raw material manufacturing, doubling capacity, and leveraging industry trends for revenue expansion in the coming years.

Lifecore Biomedical reports revenue growth and strategic investments for growth

Lifecore Biomedical's Q4 2023 performance showed revenue growth and strategic investments in capacity expansion. While facing challenges in maintaining gross profit margins, the company's focus on CDMO services and development projects presents growth opportunities. Uncertainties surrounding fiscal year 2024 guidance indicate ongoing strategic review processes and potential impacts on future performance.

Lifecore Biomedical reports robust fiscal 2024 performance amidst flat 2025 outlook

Lifecore Biomedical demonstrated strong financial performance in fiscal 2024 with notable revenue and profit increases. While challenges like divestitures impacted the company, strategic measures such as workforce reduction and growth strategies position Lifecore for future success. Opportunities lie in the potential for continued financial growth and revenue generation through targeted strategies.

Lifecore Biomedical reports revenue growth amidst challenges, eyes sustainable growth

Lifecore Biomedical Inc showcased revenue growth and operational improvements in Q1 2025, despite facing a net loss. The company's focus on customer acquisition, expansion, and financial stability presents opportunities for future growth and enhanced performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Lifecore investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secu.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) investors concerning the Company's possible violations of federal securities laws. On March 20, 2024, Lifecore filed restated financial statements for fiscal year 2021 and 2022 to “correct errors involving the calculation of capitalized interest, valuation of inventories, and certain other adjustments related to previously.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)---- $LFCR #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQ: LFCR). Investors who purchased Lifecore securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. Investigation Details: On March 20, 2024, Lifecore announced that its Board of Directors had concluded its revi.

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 20, 2024, Lifecore filed restated financial statements for fiscal year 2021 and 2022 to “correct errors involving the calculation of capitalized interest, va.

The Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of Investors

CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company's independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company's independent registered public accounting firm for the Company's fiscal year ending May 26, 2024 following the filing of the Company's Annual Report on Form 10-K. Lifecore's board of directors has initiated a search for a replacement.

Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lifecore Biomedical, Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Lifecore Biomedical, Inc. (NASDAQ: LFCR). (“Lifecore” or the “Company”). We are looking into whether the Company or its executives failed to disclose vital information to investors, leading to losses on their investments. If you have purchased Lifecore securities and have experienced losses, we encourage you to join our investigation to potentially make claims.

Lifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLP

NEW YORK--(BUSINESS WIRE)---- $LFCR #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ:LFCR). The investigation concerns whether Lifecore and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On March 20, 2024, Lifecore filed its Annual Report on Form 10-K for the fiscal year ended May 28, 202.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)

Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.

Lifecore (LFCR) Down 30% on Ending Strategic Review With No Deal

Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q

Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's Securities

Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements

Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements

Agriforce Growing Systems Ltd

Bit Brother Ltd

The Real Good Food Co

S&W Seed

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 5 Risk Off Stocks That May Explode This Quarter - AgriFORCE Growing Systems (NASDAQ:AGRI), Bit Brother (NASDAQ:BETS)

CHASKA, Minn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update.

Lifecore Biomedical Provides Business Update

CHASKA, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that the U.S. Department of Justice (the “DOJ”) has declined to prosecute the Company for violations of the Foreign Corrupt Practices Act (the “FCPA”) involving the Company's formerly-held subsidiary, Yucatan Foods L.P.

Company Reaches Favorable Resolution Regarding Previously-Disclosed Investigation of Formerly-Held Subsidiary Yucatan Foods

CHASKA, Minn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on October 12, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Interim Report on Form 10-Q for the period ended August 27, 2023 (the “Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the period ended May 28, 2023 (the “Form 10-K” and, together with the Form 10-Q, the “Filings”) with the Securities and Exchange Commission.

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

ZUG, Switzerland , Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. Through this partnership, Lifecore becomes a member of SHL's recently announced Alliance Management program, an initiative created to further strengthen SHL's vertically integrated business model by facilitating customer engagement with other key players within the drug delivery ecosystem.

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

CHASKA, Minn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided an update on its delayed filings. The Company anticipates reporting its Fiscal 2024 First Quarter results in late October or early November, pending completion of its annual audit, and will make a formal announcement via press release once the date is established.

Lifecore Biomedical Provides Update for Development Portfolio and Timing of Delayed Filings

Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Lifecore Biomedical (LFCR) Report Negative Q1 Earnings? What You Should Know

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q4 2023 Results Conference Call August 31, 2023 8:30 AM ET Company Participants Jeff Sonnek - IR-ICR Jim Hall - President, CEO John Morberg - CFO Operator Good morning, and thank you for joining Lifecore's Fiscal 2023 Fourth Quarter Earnings Call. [Operator Instructions].

Lifecore Biomedical, Inc. (LFCR) Q4 2023 Earnings Call Transcript

Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.01 per share a year ago.

Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 fourth quarter and full year ended May 28, 2023.

News for Lifecore Biomedical Inc Stock (LFCR)